(Q32066353)

6 July 2017

title

Donepezil in the treatment of progressive supranuclear palsy (English)

1 reference

progressive supranuclear palsy

6 July 2017

main subject

1 reference

1

Fabbrini G

1 reference

6 July 2017

7

Meco G

1 reference

6 July 2017

Barbanti P

2

1 reference

6 July 2017

Bonifati V

3

1 reference

6 July 2017

Colosimo C

4

1 reference

6 July 2017

Gasparini M

5

1 reference

6 July 2017

Vanacore N

6

1 reference

6 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

Acta Neurologica Scandinavica

6 July 2017

published in

1 reference

6 July 2017

volume

103

1 reference

6 July 2017

issue

2

1 reference

6 July 2017

page(s)

123-125

1 reference

PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

6 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002123.X

Dopaminergic and cholinergic lesions in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002123.X

Striosomes and extrastriosomal matrix contain different amounts of immunoreactive choline acetyltransferase in the human striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002123.X

Neuronal loss in the basal nucleus of Meynert in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002123.X

Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002123.X

Physostigmine treatment of progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002123.X

Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002123.X

Neuropsychological features of progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002123.X

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002123.X

Prevalence and natural history of progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002123.X

Mesencephalic cholinergic nuclei in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002123.X

7 January 2021

inferred from DOI database lookup

Pharmacological Therapy in Progressive Supranuclear Palsy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002123.X

7 January 2021

inferred from DOI database lookup

Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002123.X

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1034/J.1600-0404.2001.103002123.X

1 reference

release_55aquv4ekvg4ldq4mvf63z2olu

6 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/55aquv4ekvg4ldq4mvf63z2olu

24 November 2022

mapped directly with Wikidata item

1 reference